Print this page
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
1. The primary objective is to determine if a novel fluorescent assay measuring dynamic parameters of immune synapse quality can be used to assess commercial T cell products.
2. The secondary objective is to determine if a novel fluorescent assay measuring dynamic parameters of the immune synapse can be used as a biomarker to associate with CAR-T cell efficacy and toxicity.
Protocol Number:
012108
Phase:
N/A
Applicable Disease Sites:
Multiple Myeloma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Scope:
Local
Participating Institutions:
- Rutgers Cancer Institute of New Jersey
- Principal Investigator
- Yun Kyoung Tiger
- Principal Investigator
For further information about clinical trials, please contact us at 732-235-7356.